AML patients | ALL patients | |
---|---|---|
Number/age/gender | ||
Number | 39 | 8 |
Age; median (variation range) | 61 (29–84) | 41 (22–79) |
Male/female | 21/18 | 6/2 |
Secondary leukemia | ||
Previous chemotherapy | 5/39 | 1/8 |
Primary MDS | 5/39 | |
Chronic myeloid leukemia | 1/39 | |
Morphological classification (FAB classification) | M0 1/39 | L1 5/8 |
M1 7/39 | L2 3/8 | |
M2 11/39 | ||
M3 2/39 | ||
M4 9/39 | ||
M5 9/39 | ||
Membrane molecule analysis | Membrane molecule expression 1: | Membrane molecule phenotype: T-ALL 2/8 |
CD13 31/39 | ALL-B lymphocyte type 6/8 | |
CD 14 5/39 | Subclassification 1 | |
CD15 14/39 | - Pro-B 2 | |
CD33 37/39 | - Pre-pre-B 2 | |
CD34 17/39 (stem cell marker) | - B-ALL 2 | |
Genetic abnormalities | ||
Number of patients examined | 36 | Coclusive cytogenetic analysis 3/8 Molecular analysis of bcr-abl translocation, 3 additional patients |
Cytogenetic analysis 2 | Normal 15/36 | Normal karyotype 0 |
Intermediate 13/36 | Multiple abnormalities 1 | |
Favourable 3/36 | Single, high-risk abnormalities: t(4;11)1 | |
Unfavourable 5/36 | Philadelphia chromosom/bcr-abl translocation 1 | |
Flt3 abnormalities | No Flt3 abnormality 17/36 | |
Flt3-ITD 16/36 | ||
Asp835 mutation 3/36 | ||
Response to chemotherapy | Patients receiving chemotherapy 23/39 | Patients receiving chemotherapy 6/8 |
Complete remission after first induction 9/23 | Death due to primary resistance or leukemia relapse within 6 months 4/6 |